The 505(b)(2) PlatformTM Announces Free Webinar on Commercialization of Value-Added Medicines

The 505(b)(2) Platform and SAAMnow collaborate to produce a series of Value-Added Medicine webinars focused on generating a better understanding of Value-Added Medicine Product Development and Commercialization

PHILADELPHIA— January 25, 2023 — Today, The 505(b)(2) Platform announced the scheduling of its first Webinar for 2023. This webinar is part of a planned series of webinars to be delivered in 2023 and developed through an ongoing collaboration between The 505(b)(2) Platform and Scientists for Advancement of Affordable Medicines (SAAMnow™). The initial webinar, Commercialization Differences Between Value-Added medicines and Innovator Products, will be held on February 22, 2023 at 12 noon (EST).
 
The free one-hour webinar will engage, educate and empower attendees on the differences between value-added medicines (VAM’s) and innovator products. The faculty will present and discuss the importance of building clinical and payer value before, during, and after launch to optimize market success. Scheduled speakers include industry experts in development and regulatory, commercialization, and market access. The webinar will help attendees understand how to best prepare and execute commercialization of value-added medicines, especially 505(b)(2) products.
 
“We are very excited to launch this series of webinars to help companies and life science professionals better understand the commercialization differences between value-added products and innovator products,” said Stephen Casey co-founder of The 505(b)(2) Platform and co-owner of Omni-HC, “To often companies commercialize a 505(b)(2) product as if it is an innovator product, when in actuality successful 505(b)(2) product commercialization requires a customized targeted approach to overcome significant market forces that sideline and derail value-added products.”

About the The 505(b)(2) Platform™
The 505(b)(2) Platform is a non-profit 506(c) business league. Its purpose is to educate and advocate for manufacturers of 505(b)(2) products on best practices in drug development and commercialization. Our mission is to enhance the understanding and acceptance of 505(b)(2) products in the development, regulatory and commercial arenas. WWW.505b2.org

Register for Webinar